- Home
- HSDT vs MYGN Comparison
HSDT vs MYGN Comparison
Compare HSDT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- MYGN
- Stock Information
- Founded
- HSDT N/A
- MYGN 1991
- Country
- HSDT United States
- MYGN United States
- Employees
- HSDT N/A
- MYGN N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HSDT Health Care
- MYGN Health Care
- Exchange
- HSDT Nasdaq
- MYGN Nasdaq
- Market Cap
- HSDT 707.6M
- MYGN 642.0M
- IPO Year
- HSDT N/A
- MYGN 1995
- Fundamental
- Price
- HSDT $18.03
- MYGN $7.64
- Analyst Decision
- HSDT Hold
- MYGN Hold
- Analyst Count
- HSDT 1
- MYGN 13
- Target Price
- HSDT N/A
- MYGN $13.50
- AVG Volume (30 Days)
- HSDT 1.9M
- MYGN 1.5M
- Earning Date
- HSDT 11-11-2025
- MYGN 11-06-2025
- Dividend Yield
- HSDT N/A
- MYGN N/A
- EPS Growth
- HSDT N/A
- MYGN N/A
- EPS
- HSDT N/A
- MYGN N/A
- Revenue
- HSDT $295,000.00
- MYGN $832,900,000.00
- Revenue This Year
- HSDT N/A
- MYGN $0.17
- Revenue Next Year
- HSDT $75.13
- MYGN $6.19
- P/E Ratio
- HSDT N/A
- MYGN N/A
- Revenue Growth
- HSDT N/A
- MYGN 3.83
- 52 Week Low
- HSDT $5.37
- MYGN $3.76
- 52 Week High
- HSDT $1,200.00
- MYGN $26.52
- Technical
- Relative Strength Index (RSI)
- HSDT 64.74
- MYGN 57.10
- Support Level
- HSDT $12.50
- MYGN $7.04
- Resistance Level
- HSDT $20.50
- MYGN $8.25
- Average True Range (ATR)
- HSDT 2.16
- MYGN 0.38
- MACD
- HSDT -0.07
- MYGN -0.06
- Stochastic Oscillator
- HSDT 50.83
- MYGN 54.77
About HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.